{"filings":[{"id":1002076,"accession_number":"0001193125-26-267830","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2026-06-11T20:59:06+00:00","items":["5.07"],"status":"ready","headline":"Nkarta shareholders elect directors, approve auditor and say-on-pay, choose 1-year frequency","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Ali Behbahani and Zachary Scheiner elected as Class III directors with 32.3M and 37.3M votes for, respectively.","Ernst & Young ratified as auditor for FY2026 with 53.7M for, 76K against, 20K abstain.","Advisory say-on-pay approved with 43.5M for, 3.3M against, 38.7K abstain.","Shareholders voted for 1-year frequency on future say-on-pay; company will hold annual votes.","Broker non-votes of 6.9M on director election and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40207,"accession_number":"0001787400-26-000012","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2026-05-12T20:04:35+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nkarta Q1 net loss $27.8M ($0.37/shr); cash $266.7M; advances NKX019 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and investments $266.7M as of Mar 31, 2026; expected to fund operations into 2029.","Net loss $27.8M ($0.37 per basic/diluted share) for Q1 2026; R&D expense $25.0M, G&A $5.9M.","FDA agreed to protocol amendments allowing outpatient dosing in community settings, re-dosing, and adding RA to Ntrust-2.","Enrollment ongoing at 4 billion cells per dose (12B total) across Ntrust-1 and Ntrust-2 for multiple autoimmune indications.","Initial clinical data from Ntrust-1 and Ntrust-2 expected at a medical conference in 2026."],"consensus_eps_estimate":-0.38,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108540,"accession_number":"0001787400-26-000008","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nkarta enters into ATM equity offering agreement for up to $100 million","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sales Agreement with Stifel for at-the-market offering of up to $100M of common stock.","Stifel to receive commission of up to 3% of gross proceeds; company controls sale parameters.","Registration statement on Form S-3 (File No. 333-294611) filed March 25, 2026.","Shares may be sold on Nasdaq Global Select Market or other venues; company retains discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108539,"accession_number":"0001787400-26-000005","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nkarta reports FY2025 net loss of $104.1M; cash runway into 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and investments $295.1M at Dec 31, 2025; expected to fund operations into 2029.","Full-year net loss $104.1M ($1.41 per share); Q4 net loss $27.4M ($0.37 per share).","NKX019 dose escalation advanced to 4 billion cells per dose in Ntrust-1 and Ntrust-2 trials.","Initial clinical data from Ntrust-1 and Ntrust-2 planned for presentation at a medical conference in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124987,"accession_number":"0001193125-25-274261","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nkarta advances NKX019 into second dose cohort; cash runway into 2029","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment in second dose-escalation cohort of NKX019 for autoimmune diseases is underway.","Lymphodepletion with fludarabine+cyclophosphamide shows deep B-cell depletion in all patients vs. partial with cyclophosphamide alone.","Cash, cash equivalents, and investments of $316.5M as of Sept 30, 2025, expected to fund operations into 2029.","Net loss of $21.7M ($0.29 per share) for Q3 2025; R&D expenses $20.2M.","Preliminary data from Ntrust-1 and Ntrust-2 expected at a medical conference in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141679,"accession_number":"0001193125-25-178949","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nkarta reports Q2 net loss of $23M, cash of $334M; NKX019 data expected H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $23.0M ($0.31 per share) for Q2 2025.","Cash, equivalents and investments of $334.0M as of June 30, 2025; runway into 2029.","R&D expenses of $20.8M; G&A expenses of $6.4M for Q2 2025.","Preliminary NKX019 autoimmune data (Ntrust-1 and Ntrust-2) expected H2 2025.","Shawn Rose, M.D., Ph.D appointed Chief Medical Officer and Head of R&D in June 2025."],"consensus_eps_estimate":-0.3621,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159578,"accession_number":"0000950170-25-082717","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"Nkarta appoints Shawn Rose as CMO & Head of R&D; David Shook resigns effective June 6","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shawn Rose, M.D. Ph.D, joins as CMO and Head of R&D starting June 23, 2025, succeeding David Shook.","Dr. Shook resigned to pursue other oncology opportunities; will consult through July 11.","Dr. Rose brings experience from Vividion, Magenta, Janssen, and BMS, with work on Sotyktu, Stelara, Tremfya.","Company reaffirms focus on allogeneic NK cell therapies for autoimmune disease.","Annual meeting results: all three Class II director nominees elected; Ernst & Young ratified as auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159577,"accession_number":"0000950170-25-071399","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nkarta Q1 net loss $32M; restructures 34% workforce; NKX019 autoimmune data due H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 net loss $32M ($0.43/share); cash, equivalents & securities $351.9M.","March 2025 restructuring cut 34% workforce; cash runway extended beyond 2029.","Ntrust-1 expanded to include primary membranous nephropathy; lymphodepletion regimen updated.","Initial NKX019 data across autoimmune indications expected H2 2025; both ISTs open.","Robert Ortmann, M.D. appointed VP Clinical Development, joining May 15, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177949,"accession_number":"0000950170-25-045231","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["2.02","2.05","5.02","8.01","9.01"],"status":"ready","headline":"Nkarta cuts workforce 34%, CFO departs; NKX019 autoimmune data due H2 2025; cash into 2029","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of 34% (53 positions) to cut costs and extend cash runway into 2029.","CFO Alyssa Levin terminates March 31; President Nadir Mahmood named principal financial officer.","Cash $380.5M as of Dec 31, 2024; expects cash to fund operations into 2029.","Net loss FY2024 $108.8M ($1.60/share), Q4 $25.9M ($0.35/share).","Preliminary NKX019 clinical data from Ntrust-1 and Ntrust-2 trials expected H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194656,"accession_number":"0000950170-24-123340","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nkarta Q3 net loss $28.3M; cash $405.3M; drops NHL, focuses NKX019 on autoimmune","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $28.3M ($0.39 per basic/diluted share) for Q3 2024; cash, equivalents, investments $405.3M.","First patient dosed in Ntrust-1 (lupus nephritis) and CUIMC IST (SLE); enrollment ongoing.","Ntrust-2 (systemic sclerosis, myositis, vasculitis) enrollment expected by year-end 2024; preliminary data in 2025.","Forgoes further NKX019 development in non-Hodgkin lymphoma; no new NHL trials planned.","Current cash expected to fund operations into late 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210959,"accession_number":"0000950170-24-097741","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K/A","filed_at":"2024-08-16T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Nkarta Q2 net loss $25M; cash $426.7M; NKX019 autoimmune trial Ntrust-2 to start by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $25.0M ($0.34 diluted EPS); R&D expense $23.1M, G&A $7.6M.","Cash & investments $426.7M expected to fund operations into late 2027.","FDA cleared second IND for NKX019 in autoimmune disease; Ntrust-2 enrollment for systemic sclerosis, myositis, vasculitis expected by year-end 2024.","Preliminary Ntrust-1 and Ntrust-2 data planned for 2025; NHL 7-day dosing cohort enrollment completed, data due late 2024.","Nadir Mahmood joined as President; David Shook promoted to CMO, Head of R&D."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210961,"accession_number":"0000950170-24-096163","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nkarta Q2 net loss $25M; cash $426.7M; plans Ntrust-2 trial by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $25.0M ($0.34 per share) for Q2 2024; R&D expenses $23.1M, G&A $7.6M.","Cash, equivalents and investments of $426.7M at June 30, 2024; expected to fund operations into late 2027.","FDA clearance received for second IND for NKX019 in autoimmune disease; Ntrust-2 enrollment expected by year-end 2024.","Preliminary data from Ntrust-1 and Ntrust-2 planned for 2025; IST in SLE/LN initiated at Columbia University.","Nadir Mahmood joined as President; David Shook promoted to CMO, Head of R&D in July 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210960,"accession_number":"0000950170-24-083761","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Nkarta appoints Nadir Mahmood as President, promotes David Shook to CMO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nadir Mahmood, former Nkarta CFO and Rezo CEO, appointed President effective July 29, 2024; shares leadership with CEO Paul Hastings.","David Shook promoted to Chief Medical Officer, Head of R&D, overseeing clinical development, regulatory, and translational science.","James Trager steps down as Chief Scientific Officer due to personal reasons, transitions to special advisory role.","Mahmood receives $530K base salary, option for 550K shares vesting over time, 50% target bonus; severance terms included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229427,"accession_number":"0000950170-24-078152","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Nkarta initiates Ntrust-1 in lupus nephritis, IND cleared for 3 more autoimmune indications","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient in screening for Ntrust-1, a trial of NKX019 in refractory lupus nephritis.","FDA cleared IND for NKX019 in systemic sclerosis, myositis, and ANCA-associated vasculitis (Ntrust-2).","Both trials are dose-escalation, open-label, multi-center, designed for up to 12 patients each.","Clinical data from Ntrust-1 and Ntrust-2 expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229426,"accession_number":"0000950170-24-073046","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["3.03","5.03","5.07","7.01","9.01"],"status":"ready","headline":"Nkarta shareholders approve doubling authorized shares; elects Dr. Vratsanos to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved increasing authorized common shares from 100M to 200M.","Elected three Class I directors: Paul Hastings, Angela Thedinga, and new member George Vratsanos.","Ratified Ernst & Young as independent auditor for fiscal 2024.","Press release highlights Dr. Vratsanos' R&D leadership at Jnana, Janssen, Novartis, Roche, BMS.","Nkarta focuses on NK cell therapy for lupus nephritis with NKX019 program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229425,"accession_number":"0000950170-24-056870","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nkarta Q1 net loss $29.5M; cash $450M; NKX019 lupus dosing on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and investments of $450.0M at March 31, 2024, including $240.1M from March offering.","Net loss of $29.5M ($0.58 per share) for Q1 2024; R&D expense $25.2M, G&A $7.5M.","First patient dosing with NKX019 in lupus nephritis expected H1 2024; IND cleared 4Q2023.","Preliminary NKX019 compressed dosing data in NHL expected mid-2024; 4/4 re-treated patients achieved CR.","Cash runway expected to fund operations into late 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247985,"accession_number":"0000950170-24-038037","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nkarta raises ~$225.2M in underwritten offering of stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 21,010,000 shares at $10.00 and pre-funded warrants for 3,000,031 shares at $9.9999.","Net proceeds of ~$225.2M after underwriting discounts and estimated expenses.","Proceeds to fund NKX019 clinical development and internal manufacturing buildout.","Pre-funded warrants exercisable immediately at $0.0001 per share, with 19.99% ownership cap.","Underwriting agreement with Leerink Partners and Cowen and Company, LLC, dated March 25, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247984,"accession_number":"0000950170-24-035613","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Nkarta shares NKX019 B-cell reconstitution and PK data from Phase 1 NHL trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["After NKX019 treatment, circulating CD19+ cells rapidly depleted; B-cell repertoire recovered with naïve, non-class-switched isotypes in 5 patients at 3 months.","No patients had prior CAR T therapy; recovery pattern consistent with CAR T experience in autoimmune disease.","Preliminary PK data from 2 patients with DLBCL show similar NKX019 exposure after Flu/Cy vs Cy alone lymphodepletion.","B-cell recovery confirmed by single-cell RNA profiling, showing naïve and intermediate B cell transcriptome profiles.","Company highlights potential of NKX019 for autoimmune diseases such as lupus nephritis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247983,"accession_number":"0000950170-24-034710","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nkarta reports FY2023 net loss $117.5M; deprioritizes NKX101, advances NKX019 in autoimmune","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 net loss of $117.5M ($2.40 per basic/diluted share).","Year-end cash, equivalents & investments $250.9M; expected to fund operations into 2026.","NKX019 lupus nephritis trial on track to dose first patient in H1 2024.","NKX101 AML program deprioritized after CR/CRi rate 5/20 vs 4/6 in first 6 patients.","NKX019 compressed dosing cohort in NHL; preliminary data expected mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247982,"accession_number":"0000950170-24-002733","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nkarta posts updated corporate presentation; no specific material updates in filing excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company made available an updated corporate presentation dated January 2024.","Presentation focuses on NK cell engineering for cancer and autoimmune diseases.","Filed exhibit contains only a title slide; no financial data or milestones provided.","Presentation is furnished under Regulation FD and not filed with the SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265430,"accession_number":"0000950170-23-062019","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nkarta reports Q3 net loss $25.6M; cash $278.4M; extends runway into 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $25.6M ($0.52 per share) for Q3 2023; R&D expenses $22.2M, G&A $7.1M.","Cash and investments $278.4M as of Sep 30, 2023; cost containment extends cash runway into 2026.","FDA cleared IND for NKX019 in lupus nephritis; first patient dosing expected H1 2024.","Workforce reduced ~10%; operations centralization and manufacturing optimization underway.","Clinical data updates in 2024: NKX101 AML, NKX019 NHL compressed dosing, LN."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265429,"accession_number":"0000950170-23-053645","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2023-10-17T23:59:59+00:00","items":["2.02","2.05","8.01","9.01"],"status":"ready","headline":"Nkarta gets FDA IND clearance for NKX019 in LN; cuts workforce 10%, extends cash runway","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for NKX019 (CAR NK) for lupus nephritis; enrollment starts H1 2024; up to 12 patients.","RIF of 18 employees (~10% workforce); $1M-$1.5M severance costs in Q4 2023; extends cash runway into 2026.","Preliminary cash $278.4M as of Sep 30, 2023; cash runway extended one year into 2026.","NKX019 NHL: new compressed dosing cohort (Days 0,3,7) for LBCL; prior expansion cohorts discontinued.","Clinical updates in 2024: NKX101 AML H1, NKX019 NHL mid-2024, NKX019 LN in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265428,"accession_number":"0000950170-23-053528","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2023-10-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nkarta schedules Oct 17 call to discuss clinical program updates and cost measures","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Conference call will be held on Tuesday, October 17, 2023 at 8:00 a.m. ET.","Topics include clinical program updates, organizational cost measures, and resource prioritization.","Registration link provided in press release; replay will be available on Nkarta’s website.","No specific financial or clinical data disclosed in the announcement.","Call intended to support clinical milestones and pipeline expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282624,"accession_number":"0000950170-23-040948","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nkarta Q2 net loss $33.3M ($0.68/share); cash $302.2M; NKX101 shows 67% CR/CRi with Flu/Ara-C","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $302.2M as of June 30, 2023; cash runway into 2025.","R&D expense $25.1M; G&A $11.7M; non-cash impairment charge $4.1M on right-of-use assets.","NKX101: 4/6 CR/CRi (67%) in AML patients after Flu/Ara-C lymphodepletion; no dose-limiting toxicities.","NKX019 updated data from Phase 1 NHL trial presented at EHA and ICML; expansion cohorts enrolling.","Alyssa Levin appointed CFO and Chief Business Officer effective July 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282623,"accession_number":"0000950170-23-031624","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2023-07-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Nkarta appoints Alyssa Levin as CFO and Business Officer effective July 1","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Annual base salary of $450k, sign-on bonus of $20k, and a stock option for 442,400 shares.","Option vests 25% on July 1, 2024, then monthly over 36 months; exercise price = June 30 closing.","Levin previously CFO at ViaCyte (acquired by Vertex), Tentarix, and Bird Rock Bio.","Target annual incentive bonus set at 40% of base salary.","Company is developing engineered NK cell therapies for cancer (NKX101, NKX019)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301891,"accession_number":"0000950170-23-029955","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2023-06-27T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Nkarta NKX101 achieves 67% CR/CRi in AML Phase 1 with modified lymphodepletion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In Flu/Ara-C cohort (n=6), NKX101 showed 67% CR/CRi rate (4/6) and 50% CR rate (3/6); 2 CRs MRD-negative.","In Flu/Cy highest-dose cohort (n=18), CR/CRi rate was 22% (4/18) and CR rate 17% (3/18).","NKX101 well tolerated; no dose-limiting toxicities, limited CRS/ICANS/GvHD across all doses.","Expansion cohort with Flu/Ara-C to enroll 12-20 more patients; clinical update expected 1H 2024.","Patients heavily pre-treated (median 2 prior lines, 90%+ prior venetoclax); majority poor-risk disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301890,"accession_number":"0000950170-23-029860","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2023-06-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nkarta to host conference call to discuss updated NKX101 clinical data on June 27","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Press release on June 26, 2023 announces conference call for June 27, 2023 at 8:00 a.m. ET.","Call to review updated clinical data from ongoing trial of NKX101, an allogeneic CAR NK cell therapy targeting NKG2D ligands.","Company ticker NKTX; slides will be available on Nkarta's website.","Replay of call archived for approximately four weeks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301889,"accession_number":"0000950170-23-027263","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Nkarta shareholders approve officer exculpation amendment, elect directors at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to certificate of incorporation to allow officer exculpation under Delaware law, effective June 7, 2023.","Elected Class III directors Ali Behbahani (27.3M for) and Zachary Scheiner (37.5M for) for terms ending 2026.","Ratified Ernst & Young as independent auditor for FY2023 with 43.4M votes in favor.","Amendment filed as Exhibit 3.1 to the Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301888,"accession_number":"0000950170-23-021218","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nkarta Q1 net loss $30.8M, cash $332.1M, CFO resigning","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $30.8M ($0.63 per share) for Q1 2023; R&D expenses $26.1M, G&A $8.2M.","Cash and equivalents $332.1M as of March 31, 2023; runway expected into 2025.","CFO Nadir Mahmood resigning effective June 30, 2023; successor search underway.","NKX101 clinical update planned for Q2 2023; NKX019 update in H2 2023.","Preclinical data on NK cell engineering presented at AACR 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321635,"accession_number":"0000950170-23-010937","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Nkarta CFO Nadir Mahmood resigns effective June 30, 2023; clinical timelines reaffirmed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Nadir Mahmood resigns to become CEO of a private biotech; effective June 30, 2023.","Nkarta initiates external search for new CFO.","NKX101 clinical update on track for Q2 2023; NKX019 update expected in full year 2023.","Mahmood will remain until June 30 to ensure smooth transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321634,"accession_number":"0000950170-23-008452","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2023-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nkarta reports FY2022 net loss of $113.8M; cash $354.9M; NKX101/019 updates in 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $113.8M ($2.61 diluted EPS) for FY2022; Q4 loss $32.6M ($0.67).","Cash and investments total $354.9M; management expects runway to fund operations into 2025.","R&D expenses $90.9M (FY) and $26.8M (Q4); G&A $28.1M (FY) and $8.1M (Q4).","NKX101: 60% CR in AML at higher doses; additional data expected H1 2023.","NKX019: 70% CR in B-cell malignancies; dose expansion enrolling; updated data expected in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321633,"accession_number":"0000950170-23-000520","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nkarta promotes David R. Shook, M.D., to Chief Medical Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Shook joined Nkarta in 2020 and was appointed VP, Clinical Development in 2022.","He has extensive cell therapy development experience, including first-in-human trials with CD19 CAR-NK cells.","Dr. Shook co-developed the membrane-bound IL-15 component of Nkarta’s NK cell platform.","He continues as a practicing pediatric oncologist and transplant physician.","Prior Nkarta, he was at St. Jude Children’s Research Hospital in the lab of scientific founder Dario Campana."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339732,"accession_number":"0000950170-22-026020","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2022-12-05T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Nkarta: 70% CR at higher NKX019 doses in NHL; no neurotoxicity observed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["7 of 10 NHL patients at 1B and 1.5B cell doses achieved complete response (70% CR, 80% ORR) across histologies including LBCL.","No dose-limiting toxicity, ICANS, GvHD, or >Gr3 CRS; safety profile supports outpatient administration.","Durable responses >6 months seen; 5 CRs after one cycle, 3 partial responses deepened to CR with additional cycles.","Dose expansion open: monotherapy in LBCL (CAR T naive/experienced) and combination with rituximab.","Conference call held Dec 5, 2022; NKX019 is an off-the-shelf allogeneic CAR-NK therapy targeting CD19."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339731,"accession_number":"0000950170-22-025995","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2022-12-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nkarta announces Dec 5 call to review updated NKX019 clinical data; no data in filing","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Conference call scheduled for December 5, 2022 at 8:00 a.m. ET to review updated clinical data from NKX019.","NKX019 is a CD19-directed CAR NK cell therapy for cancer; no specific data provided in the press release.","Slides will be posted on Nkarta's website; a replay will be available for 4 weeks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339730,"accession_number":"0000950170-22-023827","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nkarta Q3 2022 net loss $28.3M; cash $395.1M; NKX019 dose expansion opened","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $28.3M ($0.58 per share); R&D expense $23.4M, G&A $6.8M.","Cash, equivalents, and investments $395.1M; expected to fund operations into 2025.","NKX019 dose expansion cohorts opened; clinical update expected by year-end 2022.","NKX101 data for r/r AML timeline pushed to first half of 2023.","SITC presentations on NKX019+CD20 mAb combination and scalable NK cell manufacturing."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357067,"accession_number":"0000950170-22-016868","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nkarta Q2 net loss $27M; NKX101 AML 60% CR, NKX019 NHL 50% CR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2022 net loss $27.0M ($0.61/share); cash & investments $415.0M, sufficient into 2025.","NKX101 Phase 1: 3/5 AML patients at higher dose achieved CR (60%); 2 of 3 MRD-negative.","NKX019 Phase 1: 3/6 NHL patients at higher dose achieved CR (50%); included DLBCL and MCL.","Raised ~$215.6M net from public offering in April 2022; lease amendments add $15M tenant improvements.","Promoted leaders: Dr. Brandenberger to CTO, Yvonne Li to CAO, Dr. Shook to VP Clinical Dev."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375620,"accession_number":"0000950170-22-011483","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nkarta stockholders elect three Class II directors, ratify Ernst & Young as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Michael Dybbs re-elected with 27,209,832 for, 770,122 withheld; 1,948,226 broker non-votes.","Simeon George re-elected with 26,891,767 for, 1,088,187 withheld; same broker non-votes.","Leonne Patterson re-elected with 27,240,830 for, 739,124 withheld; same broker non-votes.","Ratification of Ernst & Young auditor: 29,828,606 for, 98,705 against, 869 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375619,"accession_number":"0000950170-22-010075","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2022-05-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Nkarta CMO Kanya Rajangam resigns; David Shook named VP Clinical Development","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Kanya Rajangam resigns as CMO effective June 5, 2022, to oversee R&D at a private biotech.","Dr. David Shook appointed VP Clinical Development, leading all clinical and regulatory activities.","Shook is a practicing pediatric hematologist/oncologist and early NK cell therapy pioneer.","Nkarta's NKX101 and NKX019 programs continue; expects to submit updated data for a medical meeting in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375618,"accession_number":"0000950170-22-009659","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nkarta reports Q1 net loss $26.0M; shares positive AML/NHL clinical data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $26.0M ($0.79/share); cash, equivalents & short-term investments $219.1M at 3/31/22, plus $215.5M net from April offering, pro forma >$400M.","NKX101 Phase 1: 3 of 5 heavily pre-treated AML patients at higher dose achieved complete response; 2 of 3 CRs MRD-negative.","NKX019 Phase 1: 5 of 6 NHL patients responded, 3 CR (including DLBCL and MCL); no CRS, GvHD, or ICANS observed in either study.","Anticipates additional NKX101 and NKX019 dose-escalation data in H2 2022.","Angela Thedinga appointed to Board of Directors in March 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375617,"accession_number":"0000950170-22-006547","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2022-04-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nkarta completes $215.5M public offering of 15.3M shares at $15/sh","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 13.33M firm shares plus 2M option shares at $15.00/sh.","Net proceeds ~$215.5M after underwriting discounts and expenses.","Proceeds to fund NKX101, NKX019 clinical development, preclinical programs, and manufacturing.","Underwriters: Cowen, SVB Securities, Evercore."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375616,"accession_number":"0001193125-22-116353","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2022-04-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nkarta reports 60% CR for NKX101 in AML; 83% ORR for NKX019 in NHL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NKX101: 3/5 AML patients at 1B/1.5B cells x3 achieved CR (60%); 2 of 3 CRs are MRD negative.","NKX019: 5/6 NHL patients at 1B cells x3 achieved response (83% ORR); 3/6 CR (50% CR).","No CRS, neurotoxicity, or GvHD reported for either program; safety profile favorable.","Both programs advancing to 1.5B cells x3 dose regimen for recommended Phase 2 dose.","Phase 1 trials continue enrolling; updated data to be submitted to future medical meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375615,"accession_number":"0000950170-22-006012","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2022-04-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nkarta to host April 25 conference call to discuss Phase 1 data for NKX101 and NKX019","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Conference call scheduled for April 25, 2022 at 8:00 a.m. ET to review preliminary clinical data.","NKX101 and NKX019 are engineered NK cell therapy candidates in ongoing Phase 1 trials.","Leading investigators from the two clinical trials will join management for the discussion.","Webcast and accompanying slides available on Nkarta’s website with replay for ~4 weeks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393955,"accession_number":"0000950170-22-004854","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2022-03-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Nkarta appoints manufacturing executive Angela Thedinga to its Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Angela Thedinga as independent Class I director effective March 28, 2022.","Received stock option for 32,000 shares vesting in three equal annual installments.","Will receive annual cash retainer of $40,000, pro-rated for Q1 2022.","Thedinga most recently CTO of Adverum Biotechnologies; previously at AveXis/Novartis Gene Therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393954,"accession_number":"0000950170-22-004087","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2022-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nkarta reports full year 2021 net loss of $86.1M; NKX101 data expected 1H 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2021 net loss $86.1M ($2.62/share); Q4 net loss $22.8M ($0.69/share).","Cash and investments $240.2M as of Dec 31, 2021; cash runway into 2H 2023.","R&D expenses $63.4M full year; G&A $23.0M; non-cash stock-based comp $14.5M.","NKX101 Phase 1 monotherapy data (AML/MDS) expected 1H 2022; NKX019 data in 2022.","NKX101 received FDA orphan drug designation for AML; protocol amendments filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412507,"accession_number":"0001564590-21-056198","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nkarta reports Q3 net loss of $22.4M; NKX101 data pushed to 1H 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.4M ($0.68 per share); R&D expense $16.6M, G&A $5.8M.","Cash, equivalents, restricted cash and short-term investments totaled $259.8M; runway into at least 2H 2023.","NKX101 Phase 1 data for AML/MDS expected in 1H 2022 (updated from prior guidance).","First patients dosed in NKX019 Phase 1 for B cell malignancies; initial data expected in 2022.","Leased new 88,000 sq ft manufacturing facility and HQ to support pivotal trials and commercial launch."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412506,"accession_number":"0001564590-21-051572","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2021-10-22T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Nkarta expands headquarters lease by 8,075 sq ft; total space now 42,145 sq ft","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Leased additional 8,075 rentable sq ft (Suite 104) at 6000 Shoreline Court, South San Francisco.","Total leased premises increases to approximately 42,145 rentable square feet.","Base rent for new space starts at ~$50,469/month, increasing 3.5% annually to ~$62,039.","Tenant receives first two months rent abatement and a $121,125 tenant improvement allowance.","Lease term for expansion runs through January 31, 2029, coterminous with existing lease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412505,"accession_number":"0001564590-21-050412","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2021-10-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nkarta doses first patients in NKX019 Ph1; NKX101 initial data guided to 1H 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patients dosed in Phase 1 trial of NKX019 for CD19+ B-cell malignancies (NHL, CLL, B-ALL).","Initial data from NKX019 trial expected in 2022.","Initial data from NKX101 Phase 1 in AML/MDS now expected in first half of 2022 (previously anticipated earlier).","NKX101 cadence affected by haplomatched donor cell use, staggered enrollment, and COVID-19 disruptions.","Protocol amended to allow off-the-shelf or haplomatched cells and to shorten patient stagger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":431192,"accession_number":"0001564590-21-043995","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2021-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nkarta reports Q2 2021 net loss $21.5M; cash runway into 2H 2023; NKX101 data by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.5M ($0.66/share) for Q2 2021; R&D expenses $16.0M, G&A $5.7M.","Cash, equivalents, restricted cash, and short-term investments $280.3M as of June 30, 2021.","Initial Phase 1 data for NKX101 (CD33-targeted NK cell therapy) expected by end of 2021.","NKX019 (CD19-targeted NK) Phase 1 patient dosing expected to start in 2H 2021.","Collaboration with CRISPR Therapeutics to co-develop two CAR-NK candidates and license CRISPR/Cas9 gene editing."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":431191,"accession_number":"0001564590-21-036496","cik":1787400,"company_name":"Nkarta, Inc.","ticker":"NKTX","form_type":"8-K","filed_at":"2021-07-14T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Nkarta signs 12-year lease for 88,106 sq ft manufacturing and HQ facility in South San Francisco","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Monthly base rent starts at ~$564K, escalating to ~$823K; tenant improvement allowance up to $25.2M.","Facility will support research, development, and commercial manufacturing of NK cell therapy pipeline.","Expected operational by end of 2023; planned production for pivotal trials and commercial launch.","Nkarta retains existing 2,700 sq ft cGMP facility for early-stage clinical manufacturing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":232522413.47962382,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}